VRTOG

Veterinary Radiation Therapy Oncology Group

Executive Committee (2013)

  • Dr. John Farrelly, Chair
  • Dr. Pam Jones, Assistant Chair
  • Dr. Lisa DiBernardi, Member At Large
  • Dr. Nathan Lee, Member At Large
  • Dr. Sheri Siegel, ex-officio; President, Recognized Specialty of Radiation Oncology

VRTOG Policies & Procedures

Business Meeting Minutes

ACTIVITIES

Examining the Efficacy of Toceranib Phosphate (Palladia®) as a Primary and/or Adjuvant Agent in the Treatment of Feline Oral Squamous Cell CarcinomaFeline SCC toceranib +/- RT.pdf (Login Required) This study is currently closed – no longer recruiting patients. As of October 27, 2013, 24 patients have been enrolled in the radiation + Palladia arm, and 16 patients in the Palladia alone arm.

  • The study objective is to identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of feline oral squamous cell carcinoma.  This is a partially funded, non-randomized study examining the efficacy of toceranib alone or in combination with palliative radiation therapy using 6 Gy X 6 biweekly fractions.

Examining the Efficacy of Toceranib Phosphate (Palladia®) as a Primary and/or Adjuvant Agent in the Treatment of Canine Nasal CarcinomaCanine nasal carcinoma toceranib +/- RT.pdf (Login Required) This study is currently closed and no longer recruiting patients.  As of October 27, 2013, 47 patients have been enrolled in the radiation + Palladia arm (goal 45), and 16 patients in the Palladia alone arm (goal 15).

  • The study objective is to identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of canine nasal carcinoma. This is a partially funded, non-randomized study examining the efficacy of toceranib alone or in combination with radiotherapy using 4.2 Gy X 10 daily fractions.

Coarse fraction RT and/or ONCEPT™ Melanoma Vaccination for Canine Oral MelanomaCanine oral melanoma study outline.pdf, Canine oral melanoma study data sheets.pdf This study is currently recruiting patients THIS IS THE LAST CALL FOR PATIENTS (as of 2/27/14).

  • The study objective is to evaluate the effect of coarse-fraction radiotherapy (8 Gy X 4 weekly fractions) in combination with the ONCEPT™ melanoma vaccine on the outcome of dogs with malignant oral melanoma.  Data for three treatment groups (concurrent RT and vaccine; RT alone; vaccine alone) will be collected.  Treatment selection will be based on owner’s preference. While this is designed as a prospective, non-randomized study, retrospective cases are welcome as long as inclusion criteria are met.

Guidelines and Quality Assurance Program Recommendations

Grant Submission Format

VRTOG Radiation Morbidity Scoring Scheme

 

VRTOG Membership

Annual Institutional VRTOG Membership

Pay the Annual Institutional VRTOG Membership Fee (US $100) securely using PayPal. A PayPal account is not required.